Pfizer Ventures joined Mission’s other existing investors to push the mitochondria-focused drug developer’s lifetime funding to approximately $143m.
Mission Therapeutics, a UK-based drug treatment developer based on University of Cambridge research, yesterday secured $15m of funding from a consortium led by Pfizer Ventures, the strategic investment arm of pharmaceutical firm Pfizer.
All of Mission’s existing shareholders contributed on a pro-rata basis, it said, without explicitly listing any of them. It is unknown whether any previous backers subsequently exited the spinout.
Founded in 2011, Mission Therapeutics is targeting multiple diseases with drug molecules that inhibit deubiquitylating (DUB)…
